Conclusion: SCG2 and CCL19 are potential novel biomarkers of Calcific aortic valve disease (CAVD) and may play important roles in the biological process of Calcific aortic valve disease (CAVD). The gene discussed is CCL19; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.